Mounjaro vs. Trulicity
Mounjaro and Trulicity are injectable GLP-1 agonists for type 2 diabetes, but Mounjaro, a dual GIP and GLP-1 agonist, provides superior HbA1c reductions and enhanced weight loss. Both are used off-label for weight management, though Mounjaro’s results are more pronounced. Side effects, including nausea, overlap, though Mounjaro’s dual mechanism may elevate the risk of thyroid tumors. Mounjaro costs $1,135/month, compared to Trulicity’s $875/month. Neither drug currently faces shortages.
Enhances the effects of both incretin hormones. GIP improves insulin sensitivity and enhances fat metabolism, while GLP-1 reduces appetite, delays gastric emptying, and promotes insulin secretion, making it effective for blood sugar control and weight loss.
Common Side Effects
Nausea, vomiting, diarrhea, decreased appetite, and indigestion
Serious Potential Side Effects
Pancreatitis, thyroid tumors (potential risk), gallbladder issues, kidney problems, and serious allergic reactions
Slows gastric emptying, reduces appetite, and enhances feelings of fullness, leading to lower calorie intake. It also stimulates insulin release and reduces glucagon secretion, improving blood sugar control.
Common Side Effects
Nausea, diarrhea, vomiting, fatigue, and decreased appetite.
Serious Potential Side Effects
Pancreatitis, thyroid tumors (potential risk), gallbladder issues, kidney problems, and serious allergic reactions